ROIV President Eric Venker sells 200,000 shares at $30.27; scheduled 10b5-1 plan. Holds 1.61M post-sale.
Eric Venker, President & Immunovant CEO, sold 200,000 shares at $30.27 on 2026-05-22 as part of a pre-arranged 10b5-1 trading plan. This is a scheduled, non-discretionary transaction. His holding dropped from 1.81M to 1.61M shares (-11.0% vs pre-transaction holdings). The company is unprofitable with annual revenue growth of -71.6%, though the stock trades within its 52-week range at $29.96 current price. Prior same-ticker sales at ROIV show mixed 30/90-day post-sale price performance (ranging from +0.2% to +22.3% over 30 days), and cross-ticker selling history averaged 90-day returns of +31.3%. The scheduled nature of this transaction limits inference about insider sentiment; it reflects pre-planned execution rather than discretionary decision-making.